DermTech, Inc. Stock Price, News & Analysis

CasperLabs has appointed Michael Dobak as its first Chief Marketing Officer, tasked with enhancing the brand's visibility and growth in the enterprise blockchain sector. Dobak brings over 25 years of experience from leading brands like IBM and Samsung at Ogilvy and has held key positions at BLOCKv and DermTech (NASDAQ: DMTK). His expertise is expected to accelerate business adoption of blockchain technologies, as CasperLabs marks a successful year with multiple global partnership deals.

DermTech, Inc. (NASDAQ: DMTK) has granted restricted stock units (RSUs) to a new employee, totaling 51,934 shares under its 2022 Inducement Equity Incentive Plan. The RSUs were approved on March 23, 2022, and will vest incrementally, with the first portion of 1,791 shares vesting on March 5, 2023. The remaining shares will vest 25% on the same date and the rest in quarterly installments until March 5, 2026, contingent on continued employment. DermTech specializes in non-invasive skin genomics to improve dermatological care.

DermTech, Inc. (NASDAQ: DMTK) has announced a significant advancement in melanoma detection. A study published in SKIN: The Journal of Cutaneous Medicine, led by Dr. Daniel M. Siegel, highlights the Pigmented Lesion Assay (PLA) as a cost-effective solution for assessing skin lesions. The study indicates potential annual net savings of $0.54 PMPM for health plans over three years with the PLA's incorporation. This non-invasive method reduces unnecessary biopsies and enhances patient care while aiming to improve overall health outcomes.

DermTech reported robust growth in its Q4 and full-year 2021 results, with a 42% increase in billable sample volume to approximately 11,780 and a 90% rise in assay revenue to $3.0 million for Q4. For the full year, total revenue was $11.8 million, marking a 101% increase compared to 2020. The company ended 2021 with $228.4 million in cash. However, net loss for Q4 was $26.1 million, compared to $10.7 million loss in Q4 2020. Management projects Q1 2022 assay revenue between $3.4 million and $3.8 million.

DermTech (NASDAQ: DMTK) has announced management presentations at two upcoming healthcare conferences. The Cowen 42nd Annual Health Care Conference will take place on March 8, 2022, at 12:50 p.m. Eastern Time, followed by the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 3:20 p.m. Eastern Time. Interested parties can access live webcasts and archived presentations via DermTech’s website. The company is focused on precision dermatology through non-invasive skin genomics, aiming to improve skin cancer detection and customize treatments for inflammatory diseases.

DermTech (NASDAQ: DMTK) announced the appointment of Adelle Walker as Vice President of Consumer Products, enhancing its focus on precision dermatology through a non-invasive skin genomics platform. Walker brings over 20 years of experience from Allergan and other firms, aiming to expand DermTech’s consumer reach related to skin health. The company has launched its DermTech Melanoma Test and is developing UV damage DNA risk assessment products, responding to consumer demand for detailed skin health information.

DermTech, Inc. (NASDAQ: DMTK) will release its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. A conference call to discuss these results will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can access the call by dialing (844) 467-7114 for domestic or (409) 231-2086 for international calls, using conference ID 8994008. DermTech is focused on precision dermatology through a non-invasive skin genomics platform aimed at improving early detection of skin cancers and customizing treatments.

DermTech, Inc. (NASDAQ: DMTK) announced its participation in key healthcare conferences. Management will meet with investors at the 11th Annual SVB Leerink Global Healthcare Conference on February 16-17, 2022. Additionally, they will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 1:00 p.m. Eastern Time. DermTech is focused on precision dermatology, utilizing a non-invasive skin genomics platform for early skin cancer detection and treatment customization.

BioIQ and DermTech have announced a partnership to include the DermTech Melanoma Test in BioIQ's health testing options, enhancing access to precision genomics for patients. Initially available in Florida, the program aims to streamline melanoma testing using non-invasive methods. The collaboration addresses delays in medical care exacerbated by the COVID-19 pandemic, offering patients convenient teledermatology services. This agreement is positioned to lower healthcare costs for employers and improve diagnostic experiences for patients.